CA Patent

CA3196539A1 — Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies

Assigned to Genentech Inc · Expires 2022-05-12 · 4y expired

What this patent protects

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferati…

USPTO Abstract

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).

Drugs covered by this patent

Patent Metadata

Patent number
CA3196539A1
Jurisdiction
CA
Classification
—
Expires
2022-05-12
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.